DB-1310 Antibody 

DB-1310 Antibody is a monoclonal antibody inhibitor targeting HER3. DB-1310 Antibody can be used to synthesize the antibody-drug conjugate (ADC) DB-1310. DB-1310 Antibody is applicable to research related to HER3-positive solid tumors, non-small cell lung cancer, breast cancer, colon cancer and prostate cancer^[1].

Human

DB-1310 (100 nM; overnight coating) exhibits high, selective binding affinity for human and cynomolgus monkey HER3 with an EC₅₀ of 0.044 nM, and does not cross-react with other EGFR family members or murine HER3^[1].
DB-1310 (up to 500 nM; 1 h at 4°C) binds a novel HER3 epitope that does not overlap with the epitope recognized by patritumab^[1].
DB-1310 (0.1-0.5 nM; 4 days) exerts a bystander killing effect, inducing cytotoxicity in HER3-negative HEK293 cells only when cocultured with HER3-positive HEK293-ERBB3 cells^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

DB-1310 (1-3 mg/kg; i.v.; biweekly; 4 weeks) exerts potent dose-dependent tumoricidal activity in NCI-H441 NSCLC xenografts, achieving a maximum tumor growth inhibition rate greater than 95%^[1].
DB-1310 (3-10 mg/kg; i.v.; biweekly; 4 weeks) exerts potent dose-dependent tumoricidal activity in LU1542 NSCLC patient-derived xenografts, achieving a maximum tumor growth inhibition rate greater than 80%^[1].
DB-1310 (1-3 mg/kg; i.v.; biweekly; 4 weeks) exerts superior tumoricidal activity compared to HER3-DXd in HCC1569 breast cancer xenografts^[1].
DB-1310 (1-3 mg/kg; i.v.; biweekly; 4 weeks) exerts superior tumoricidal activity compared to HER3-DXd in Colo205 colon cancer xenografts^[1].
DB-1310 (3-10 mg/kg; i.v.; biweekly; 4 weeks) exerts potent tumoricidal activity in PR9586 prostate cancer patient-derived xenografts, achieving near-complete tumor growth inhibition^[1].
DB-1310 (3-10 mg/kg; i.v.; biweekly; 4 weeks) exerts dose-dependent tumoricidal activity in PR9587 prostate cancer patient-derived xenografts^[1].
DB-1310 (6 mg/kg; i.v.; single injection) exerts tumoricidal activity in NCI-H1975 EGFR-mutant NSCLC xenografts, with synergistic enhancement when combined with osimertinib^[1].
DB-1310 (3-10 mg/kg; i.v.; biweekly; 4 weeks) exerts tumoricidal activity in osimertinib-resistant EGFR-mutant NSCLC patient-derived xenografts^[1].
DB-1310 (1-5 mg/kg; i.v.; single injection) induces time- and dose-dependent DNA damage in NCI-H441 NSCLC xenografts, as measured by increased phosphorylated Histone 2AX levels^[1].
DB-1310 (15-45 mg/kg; i.v.; once every 2 weeks; 3 total doses) exhibits an acceptable safety profile in cynomolgus monkeys, with a highest non-severely toxic dose of 45 mg/kg and reversible treatment-related effects^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

2065  [NCBI]

P21860

ERBB3/HER3

ELISA, FACS, Functional assay

Unconjugated

The product can be reconstituted/diluted with sterile PBS or saline.

[DB-1310 Antibody]

Please store the product under the recommended conditions in the Certificate of Analysis.

• [1]. Li X, et al. DB-1310, an ADC comprised of a novel anti-HER3 antibody conjugated to a DNA topoisomerase I inhibitor, is highly effective for the treatment of HER3-positive solid tumors. J Transl Med. 2024;22(1):362. Published 2024 Apr 17.  [Content Brief]